| Yefim Genson, DO | |
|
9620 Metropolitan Ave, Forest Hills, NY 11375-6625 | |
| (718) 793-2020 | |
| Not Available |
| Full Name | Yefim Genson |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 11 Years |
| Location | 9620 Metropolitan Ave, Forest Hills, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417397852 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 278913 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sajid Malik, Md Pc | 6103955265 | 11 |
News Archive
For a skin cell to do its job, it must turn on a completely different set of genes than a liver cell — and keep genes it doesn't need switched off. One way of turning off large groups of genes at once is to send them to "time-out" at the edge of the nucleus, where they are kept quiet. New research from Johns Hopkins sheds light on how DNA gets sent to the nucleus' far edge, a process critical to controlling genes and determining cell fate.
ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.
A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.
Transient ischemic attack (TIA) patients receive less aggressive diagnostic testing, treatment and education compared to stroke patients, which is a missed opportunity to prevent permanent disability or death, researchers reported at the American Stroke Association's International Stroke Conference 2005.
› Verified 4 days ago
| Entity Name | Reich Medical And Surgical Eyecare,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700971496 PECOS PAC ID: 7113819004 Enrollment ID: O20091008000126 |
News Archive
For a skin cell to do its job, it must turn on a completely different set of genes than a liver cell — and keep genes it doesn't need switched off. One way of turning off large groups of genes at once is to send them to "time-out" at the edge of the nucleus, where they are kept quiet. New research from Johns Hopkins sheds light on how DNA gets sent to the nucleus' far edge, a process critical to controlling genes and determining cell fate.
ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.
A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.
Transient ischemic attack (TIA) patients receive less aggressive diagnostic testing, treatment and education compared to stroke patients, which is a missed opportunity to prevent permanent disability or death, researchers reported at the American Stroke Association's International Stroke Conference 2005.
› Verified 4 days ago
| Entity Name | Sajid Malik, Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215161047 PECOS PAC ID: 6103955265 Enrollment ID: O20100527000519 |
News Archive
For a skin cell to do its job, it must turn on a completely different set of genes than a liver cell — and keep genes it doesn't need switched off. One way of turning off large groups of genes at once is to send them to "time-out" at the edge of the nucleus, where they are kept quiet. New research from Johns Hopkins sheds light on how DNA gets sent to the nucleus' far edge, a process critical to controlling genes and determining cell fate.
ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.
A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.
Transient ischemic attack (TIA) patients receive less aggressive diagnostic testing, treatment and education compared to stroke patients, which is a missed opportunity to prevent permanent disability or death, researchers reported at the American Stroke Association's International Stroke Conference 2005.
› Verified 4 days ago
| Entity Name | Sight Medical Doctors Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487077483 PECOS PAC ID: 5991935173 Enrollment ID: O20140310000579 |
News Archive
For a skin cell to do its job, it must turn on a completely different set of genes than a liver cell — and keep genes it doesn't need switched off. One way of turning off large groups of genes at once is to send them to "time-out" at the edge of the nucleus, where they are kept quiet. New research from Johns Hopkins sheds light on how DNA gets sent to the nucleus' far edge, a process critical to controlling genes and determining cell fate.
ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.
A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.
Transient ischemic attack (TIA) patients receive less aggressive diagnostic testing, treatment and education compared to stroke patients, which is a missed opportunity to prevent permanent disability or death, researchers reported at the American Stroke Association's International Stroke Conference 2005.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yefim Genson, DO 9620 Metropolitan Ave, Forest Hills, NY 11375-6625 Ph: (718) 793-2020 | Yefim Genson, DO 9620 Metropolitan Ave, Forest Hills, NY 11375-6625 Ph: (718) 793-2020 |
News Archive
For a skin cell to do its job, it must turn on a completely different set of genes than a liver cell — and keep genes it doesn't need switched off. One way of turning off large groups of genes at once is to send them to "time-out" at the edge of the nucleus, where they are kept quiet. New research from Johns Hopkins sheds light on how DNA gets sent to the nucleus' far edge, a process critical to controlling genes and determining cell fate.
ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.
A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.
Transient ischemic attack (TIA) patients receive less aggressive diagnostic testing, treatment and education compared to stroke patients, which is a missed opportunity to prevent permanent disability or death, researchers reported at the American Stroke Association's International Stroke Conference 2005.
› Verified 4 days ago
Dr. Abraham David Flug, M.D. ,P.C. Ophthalmology Medicare: Medicare Enrolled Practice Location: 10615 Queens Blvd, Forest Hills, NY 11375 Phone: 718-520-1310 Fax: 718-544-0090 | |
Dr. Mark Avi Bitton, M. D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10025 Queens Blvd, Forest Hills, NY 11375 Phone: 718-997-1400 Fax: 718-997-7921 | |
Rose A Lombardo, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 20 Cranford St, Forest Hills, NY 11375 Phone: 718-263-8512 | |
Robert Rothstein, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10814 72nd Ave, 2nd Flr, Forest Hills, NY 11375 Phone: 718-261-2727 Fax: 718-261-5302 | |
Dr. Akhilesh Singh, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10825 72nd Ave, Forest Hills, NY 11375 Phone: 718-544-5533 Fax: 718-544-3552 | |
Dr. Raphael Aharon, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10837 71st Ave, Forest Hills, NY 11375 Phone: 718-268-6120 Fax: 718-261-8622 |